Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19

In this issue of JAMA, Gottlieb et al1 report the findings of the ongoing BLAZE-1 (Blocking Viral Attachment and Cell Entry with SARS-CoV-2 Neutralizing Antibodies) trial, a randomized, phase 2/3 clinical trial of antispike neutralizing monoclonal antibody treatment among 577 outpatients with mild…

Read the full article here

Related Articles